Steven Keith Burke
Net Worth
Last updated:
What is Steven Keith Burke net worth?
The estimated net worth of Dr. Steven Keith Burke is at least $6,407,729 as of 29 Feb 2024. He owns shares worth $2,129,270 as insider, has earned $187,239 from insider trading and has received compensation worth at least $4,091,220 in Akebia Therapeutics, Inc..
What is the salary of Steven Keith Burke?
Dr. Steven Keith Burke salary is $681,870 per year as Senior Vice President of R&D and Chief Medical Officer in Akebia Therapeutics, Inc..
How old is Steven Keith Burke?
Dr. Steven Keith Burke is 64 years old, born in 1961.
What stocks does Steven Keith Burke currently own?
As insider, Dr. Steven Keith Burke owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | Senior Vice President of R&D and Chief Medical Officer | 695,840 | $3.06 | $2,129,270 |
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Steven Keith Burke insider trading
Akebia Therapeutics, Inc.
Dr. Steven Keith Burke has made 15 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 7,169 units of AKBA stock worth $11,327 on 29 Feb 2024.
The largest trade he's ever made was exercising 63,567 units of AKBA stock on 16 May 2023. As of 29 Feb 2024 he still owns at least 695,840 units of AKBA stock.
Akebia Therapeutics key executives
Akebia Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Steven Keith Burke (64) Senior Vice President of R&D and Chief Medical Officer
- Mr. David A. Spellman (48) Senior Vice President, Chief Financial Officer & Treasurer
- Mr. Dell Faulkingham (52) Senior Vice President & Chief Commercial Officer
- Mr. Jason A. Amello (57) Executive Officer
- Mr. John P. Butler MBA (61) Chief Executive Officer, Pres & Director
- Mr. Michel Dahan (46) Senior Vice President & Chief Operating Officer